An open-label, multicenter first in human study of STX-0712 in patients with resistant/refractory chronic myelomonocytic leukemia (CMML) and other hematologic malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Apr 2025 New trial record
09 Apr 2025 According to Solu Therapeutics media release, the company has procured Series A financing which will be used to complete dose escalation and expansion of the company's lead CCR2-CyTAC program, STX-0712, for the treatment of CMML, along with the development of other candidates.
09 Apr 2025 According to Solu Therapeutics media release, treatment of the first patient has been initiated in this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com